Genetic alterations in the PI3K/AKT pathway and baseline AKT activity define AKT inhibitor sensitivity in breast cancer patient-derived xenografts

PURPOSE: AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple negative metastatic breast cancer harboring PI3K/AKT-pathway alterations and in estrogen receptor-positive breast cancer in combination with fulvestrant. Here, we aimed to...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Clin Cancer Res
Main Authors: Gris-Oliver, Albert, Palafox, Marta, Monserrat, Laia, Brasó-Maristany, Fara, Òdena, Andreu, Sánchez-Guixé, Mònica, Ibrahim, Yasir H., Villacampa, Guillermo, Grueso, Judit, Parés, Mireia, Guzmán, Marta, Rodríguez, Olga, Bruna, Alejandra, Hirst, Caroline S., Barnicle, Alan, de Bruin, Elza, Reddy, Avinash, Schiavon, Gaia, Arribas, Joaquín, Mills, Gordon B., Caldas, Carlos, Dienstmann, Rodrigo, Prat, Aleix, Nuciforo, Paolo, Razavi, Pedram, Scaltriti, Maurizio, Turner, Nicholas C., Saura, Cristina, Davies, Barry R., Oliveira, Mafalda, Serra, Violeta
פורמט: Artigo
שפה:Inglês
יצא לאור: 2020
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7814659/
https://ncbi.nlm.nih.gov/pubmed/32220884
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3324
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים